Download PDF
Thromb Haemost 2005; 94(02): 286-294
DOI: 10.1160/TH05-03-0205
Theme Issue Article
Schattauer GmbH

ClfA221–550, a fibrinogen-binding segment of Staphylococcus aureus clumping factor A, disrupts fibrinogen function

Chao-Zong Liu
1   Department of Pharmacology, College of Medicine, Tzu Chi University, Hualien, Taiwan
2   Institute of Pharmacology and Toxicology, College of Life Sciences, Tzu Chi University, Hualien, Taiwan
,
Mei-Hsu Shih
3   Department of Pharmacy, Buddhist Tzu Chi Shin Dian Hospital, Taipei County, Taiwan
,
Pei-Jane Tsai
4   Department of Laboratory Medicine and Biotechnology, College of Medicine, Tzu Chi University, Hualien, Taiwan
› Author AffiliationsFinancial support: This study was supported by a grant NSC91-2320-B-320-018 from the National Science Council, Taiwan
Further Information

Publication History

Received: 25 March 2005

Accepted after major revision: 17 June 2005

Publication Date:
05 December 2017 (online)

    Permissions and Reprints

Summary

Clumping factor A (ClfA) is a surface of protein Staphylococcusaureus bacteria known for its ability to bind the C-terminus of plasma fibrinogen γ chain, which participates in mediating fibrinogen- platelet interaction and fibrin cross-linking, resulting in thrombus formation. With an aim to develop agents that block fibrinogen γ chain C-terminus,the fibrinogen-binding segment of ClfA locating at residues 221–550 was produced by recombinant technology and tested for its ability to inhibit platelet functions and fibrin clot formation. Recombinant ClfA221–550 bound fibrinogen and blocked fibrinogen-platelet interaction, resulting in the inhibition of both ADP- and collagen-induced platelet aggregations. ClfA221–550 also affected fibrin clot formation, in which factor XIIIa-mediated cross-linking of fibrinogen γ chains was abrogated by ClfA221–550 leaving the release of fibrinopeptides A and B from fibrinogen by thrombin unaltered, indicating that ClfA221–550 interfered with fibrin clot formation without affecting thrombin’s catalytic activity. Plateletmediated clot retraction depends on both platelet-fibrinogen interaction and fibrin clot formation, which makes platelet thrombus less susceptible to fibrinolysis. At the concentration that reduced platelet aggregation by 40%, ClfA221–550 prevented platelet- mediated clot retraction, whereas the glycoprotein IIb/IIIa antagonist tirofiban needed a higher concentration in inhibiting clot retraction than inhibiting platelet aggregation. By virtue of the multiple effects of ClfA221–550 on platelet aggregation, fibrin clot formation and platelet-mediated clot retraction,the binding of ClfA221–550 to fibrinogen merits further investigation for its potential as a new antithrombotic agent.

Keywords

Fibrinogen - fibrinogen-binding protein - clumping factor A - antithrombosis
 

  • References

  • 1 Bennett JS, Vilaire G. Exposure of platelet fibrinogen receptors by ADP and epinephrine. J Clin Invest 1979; 64: 1393-401.
    CrossrefPubMedGoogle Scholar
  • 2 Marguerie GA, Plow EF, Edgington TS. Human platelets possess an inducible and saturable receptor specific for fibrinogen. J Biol Chem 1979; 254: 5357-63.
    CrossrefPubMedGoogle Scholar
  • 3 Scheraga HA, Laskowski M. Jr. The fibrinogen-fibrin conversion. Adv Prot Chem 1957; 12: 1-131.
    PubMedGoogle Scholar
  • 4 Blombäck B, Hessel B, Hogg D. et al. A two-step fibrinogen- fibrin transition in blood coagulation. Nature 1978; 275: 501-5.
    CrossrefPubMedGoogle Scholar
  • 5 Siebenlist KR, Meh D, Mosesson MW. Protransglutaminase (factor XIII) mediated crosslinking of fibrinogen and fibrin. Thromb Haemost 2001; 86: 1221-8.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 6 Kanaide H, Shainoff JR. Cross-linking of fibrinogen and fibrin by fibrin-stabilizing factor (factor XIIIa). J Lab Clin Med 1975; 85: 574-97.
    PubMedGoogle Scholar
  • 7 Danesh J, Collins R, Appleby P. et al. Association of fibrinogen, C-reactive protein, albumin, or leukocyte count with coronary heart disease. JAMA 1998; 279: 1477-82.
    CrossrefPubMedGoogle Scholar
  • 8 Lowe GD, Rumley A. Fibrinogen and its degradation products as thrombotic risk factors. Ann NY Acad Sci 2001; 936: 560-5.
    CrossrefPubMedGoogle Scholar
  • 9 Koster T, Rosendaal FR, Reitsma PH. et al. Factor VII and fibrinogen levels as risk factors for venous thrombosis. A case-control study of plasma levels and DNA polymorphisms-the Leiden Thrombophilia Study (LETS). Thromb Haemost 1994; 71: 719-22.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 10 van Hylckama Vlieg A, Rosendaal FR. High levels of fibrinogen are associated with the risk of deep venous thrombosis mainly in the elderly. J Thromb Haemost 2003; 1: 2677-8.
    CrossrefPubMedGoogle Scholar
  • 11 Weisel JW, Stauffacher CV, Bullitt E. et al. A model for fibrinogen: Domains and sequence. Science 1985; 230: 1388-91.
    CrossrefPubMedGoogle Scholar
  • 12 Mosesson MW. Fibrinogen γ-chain functions. J Thromb Haemost 2003; 1: 231-8.
    CrossrefPubMedGoogle Scholar
  • 13 Podolnikova NP, Yakubenko VP, Volkov GL. et al. Identification of a novel binding site for platelet integrin αIIbβ3 (GPIIb/IIIa) and α5β1 in the γC-domain of fibrinogen. J Biol Chem 2003; 278: 32251-58.
    CrossrefPubMedGoogle Scholar
  • 14 Taubenfeld SM, Song Y, Sheng D. et al. A monoclonal antibody against a peptide sequence of fibrinogen gamma chain acts as an inhibitor of factor XIII mediated crosslinking of human fibrin. Thromb Haemost 1995; 74: 923-7.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 15 Jiroušková M, Smyth SS, Kudryk B. et al. A hamster antibody to the mouse fibrinogen γ chain inhibits platelet- fibrinogen interactions and FXIIIa-mediated fibrin cross-linking, and facilitate thrombolysis. Thromb Haemost 2001; 86: 1047-56.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 16 Scheiner T, Jiroušková M, Nagaswami C. et al. A monoclonal antibody to the fibrinogen γ-chain alters fibrin clot structure and its properties by producing short, thin fibers arranged in bundles. J Thromb Haemost 2003; 1: 2594-602.
    CrossrefPubMedGoogle Scholar
  • 17 Jiroušková M, Chereshnev I, Väänänen H. et al. Antibody blockade or mutation of the fibrinogen γ-chain C-terminus is more effective in inhibiting murine arterial thrombus formation than complete absence of fibrinogen. Blood 2004; 103: 1995-2002.
    CrossrefPubMedGoogle Scholar
  • 18 Foster TJ, Höök M. Surface protein adhesins of Staphylococcus aureus. Trends Microbiol 1998; 6: 484-8.
    CrossrefPubMedGoogle Scholar
  • 19 Hawiger JS, Timmons S, Strong DD. et al. Identification of a region of human fibrinogen interacting with staphylococcal clumping factor. Biochemistry 1982; 21: 1407-13.
    CrossrefPubMedGoogle Scholar
  • 20 McDevitt D, Francois P, Vaudaux P. et al. Molecular characterization of the clumping factor (fibrinogen receptor) of Staphylococcus aureus. Mol Microbiol 1994; 11: 237-48.
    CrossrefPubMedGoogle Scholar
  • 21 McDevitt D, Nanavaty T, House-Pompeo K. et al. Characterization of the interaction between the Staphylococcus aureus clumping factor (ClfA) and fibrinogen. Eur J Biochem 1997; 247: 416-24.
    CrossrefPubMedGoogle Scholar
  • 22 Deivanayagam CC, Wann ER, Chen W. et al. A novel variant of the immunoglobulin fold in surface adhesions of Staphylococcus aureus: crystal structure of the fibrinogen-binding MSCRAMM, clumping factor A. EMBO 2002; 21: 6660-72.
    CrossrefPubMedGoogle Scholar
  • 23 Liu C-Z, Huang T-F. Crovidisin, a collagen-binding protein isolated from snake venom of Crotalus viridis, prevents platelet-collagen interaction. Arch Biochem Biophys 1997; 337: 291-9.
    CrossrefPubMedGoogle Scholar
  • 24 Bellavite P, Andrioli G, Guzzo P. et al. A colorimetric method for the measurement of platelet adhesion in microtilter plates. Anal Chem 1994; 216: 444-50.
    PubMedGoogle Scholar
  • 25 Liu C-Z, Wu T-F, Huang T-F. et al. Trimucytin, a collagen- like snake venom protein, activates platelets independent of I-d omain within α2 subunit of α2β1 integrin. Thromb Res 2002; 105: 153-60.
    CrossrefPubMedGoogle Scholar
  • 26 Huang T-F, Liu C-Z, Ouyang C. et al. Halysin, an antiplatelet Arg-Gly-Asp-containing snake venom peptide, as fibrinogen receptor antagonist. Biochem Pharmacol 1991; 42: 1209-19.
    CrossrefPubMedGoogle Scholar
  • 27 Liu C-Z, Wang Y-W, Shen M-C. et al. Analysis of human platelet glycoprotein IIb-IIIa by fluorescein isothiocyanate- conjugated disintegrins with flow cytometry. Thromb Haemost 1994; 72: 919-25.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 28 Gorkun OV, Veklich YI, Weisel JW. et al. The conversation of fibrinogen to fibrin: recombinant fibrinogen typifies plasma fibrinogen. Blood 1997; 89: 4407-14.
    CrossrefPubMedGoogle Scholar
  • 29 Hantgan RR, Mousa SA. Inhibition of platelet-mediated clot retraction by integrin antagonists. Thromb Res 1998; 89: 271-9.
    CrossrefPubMedGoogle Scholar
  • 30 Coller BS, Peerschke EI, Scudder LE. et al. A murine monoclonal antibody that completely blocks the binding of fibrinogen to platelets produces a thrombasthenic- like state in normal platelets and binds to glycoprotein IIb and/or IIIa. J Clin Invest 1983; 72: 325-38.
    CrossrefPubMedGoogle Scholar
  • 31 Liu C-Z, Huang H-Y, Tsai P-J. et al. Blockade of glycoprotein IIb/IIIa by crotavirin, a member of disintegrins, prevents platelet from activation and aggregation by Staphylococcus aureus bacteria. Thromb Res 2005; 116: 145-55.
    CrossrefPubMedGoogle Scholar
  • 32 Farrell DH, Thiagarajan P, Chung DW. et al. Role of fibrinogen α and γ chain sites in platelet aggregation. Proc Natl Acad Sci USA 1992; 89: 10729-32.
    CrossrefPubMedGoogle Scholar
  • 33 Mosesson MW, Finlayson JS, Umfleet RA. Human fibrinogen heterogeneities. III. Identification of γ chain variants. J Biol Chem 1972; 247: 5223-7.
    CrossrefPubMedGoogle Scholar
  • 34 Farrell DH, Thiagarajan P. Binding of recombinant fibrinogen mutants to platelets. J Biol Chem 1994; 269: 226-31.
    CrossrefPubMedGoogle Scholar
  • 35 Wolfenstein-Todel C, Mosesson MW. Carboxy-terminal amino acid sequence of a human fibrinogen γ chain variant (γ’). Biochemistry 1981; 20: 6146-9.
    CrossrefPubMedGoogle Scholar
  • 36 Hantgan RR, Taylor RG, Lewis JC. Platelets interact with fibrin only after activation. Blood 1985; 65: 1299-311.
    CrossrefPubMedGoogle Scholar
  • 37 Hantgan RR. Localization of the domains of fibrin involved in binding to platelets. Biochim Biophys Acta 1988; 968: 36-44.
    CrossrefPubMedGoogle Scholar
  • 38 Cohen I, Gerrard JM, White JG. Ultastructure of clots during isometric contraction. J Cell Biol 1982; 93: 775-87.
    CrossrefPubMedGoogle Scholar